4.央行等联合印发《关于金融支持广州南沙深化面向世界的粤港澳全面合作的意见》 近日，中国人民银行、金融监管总局、中国证监会、国家外汇局、广东省人民政府联合印发《关于金融 支持广州南沙深化面向世界的粤港澳全面合作的意见》（以下简称《意见》）。《意见》从完善创新创 业金融服务、加强社会民生领域金融服务、发展特色金融服务、推进粤港澳金融市场互联互通、开展跨 境金融创新与交流、完善金融监管机制等方面提出30条重点举措，推动广州南沙在粤港澳大湾区"新发 展格局战略支点、高质量发展示范地、中国式现代化引领地"建设中更好发挥引领带动作用。 5.广东发布《金融支持促消费扩内需专项行动方案》 重要的消息有哪些 1.中美日内瓦经贸会谈联合声明 双方承诺将于2025年5月14日前采取以下举措：美国将（一）修改2025年4月2日第14257号行政令中规定 的对中国商品（包括香港特别行政区和澳门特别行政区商品）加征的从价关税，其中，24%的关税在初 始的90天内暂停实施，同时保留按该行政令的规定对这些商品加征剩余10%的关税；（二）取消根据 2025年4月8日第14259号行政令和2025年4月9日第14266号行政令对这些商品的加征 ...

Company Announcements - Zhaowei Electromechanical plans to reduce its shareholding by no more than 1.5%, equating to approximately 3.6 million shares [1] - China CNR Corporation has signed several major contracts totaling approximately 54.74 billion yuan, representing about 22.2% of its expected revenue for 2024 [2] - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a temporary suspension of its stock [2] - Sunshine Nuohua intends to acquire 100% of Langyan Life, with its stock set to resume trading [3] - Wolong Materials is planning to issue H-shares and apply for a listing on the Hong Kong Stock Exchange [3] - Hanyu Pharmaceutical has signed a joint development agreement for a novel peptide drug targeting metabolic diseases [3] - Lijun Co. confirms that its operations are normal and there are no undisclosed significant matters [3] Investments & Acquisitions - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [4] - Shuangyi Technology intends to acquire 100% of Marky Industries for 18 million AUD, along with specific assets [5] Strategic Partnerships - Sileck has signed a strategic cooperation agreement with Lihua Power for the development of large cylindrical batteries [6] - Hongchang Technology plans to invest 15 million yuan in a humanoid robot industry chain company [7] - Macroview Technology is establishing a wholly-owned subsidiary focused on artificial intelligence [8] - Yihua Jiaye has signed a strategic cooperation framework agreement with Hanyu Pharmaceutical and Hanyu Health to develop a sleep health ecosystem [9] - Wanda Film is investing in Lezi Tiancheng and will engage in strategic cooperation in IP toy product development [10] Shareholding Changes - Tiandi Online's controlling shareholder is transferring 6.97% of its shares to introduce a strategic investor [12] - Longjiang Transportation plans to reduce its shareholding by no more than 3% [13] - Boyun New Materials intends to reduce its shareholding by no more than 3% [14] - Tongrun Equipment's major shareholder plans to reduce its stake by no more than 2% [15] Financing & Capital Increase - Tangyuan Electric plans to raise no more than 864 million yuan through a private placement [16] - Shangsheng Electronics intends to issue convertible bonds to raise up to 330 million yuan [17] Other Developments - Xianju Pharmaceutical has obtained a domestic production registration certificate for Dydrogesterone tablets [18] - Rongchang Bio has received a clinical trial application acceptance notice for its antibody-drug conjugate RC278 [19] - Jiangsu Leili's subsidiary Dingzhi Technology is implementing a stock incentive plan [20]

证券代码：301367 证券简称：怡和嘉业 公告编号：2025-040 3、本协议不涉及具体交易安排及实质性业务往来，不构成关联交易，也不 构成重大资产重组，无需提交公司董事会和股东大会审议。 一、协议签署的基本情况 为充分发挥各方在睡眠健康领域的协同优势，北京怡和嘉业医疗科技股份有 限公司（以下简称"公司"）与深圳翰宇药业股份有限公司（以下简称"翰宇药 业"）、深圳翰宇健康科技有限公司（以下简称"翰宇健康"）于 2025 年 5 月 12 日共同签署了《战略合作框架协议》（以下简称"框架协议"）。基于三方在 技术研发、产品创新及渠道资源等方面的互补性，本次合作旨在整合优势资源， 构建"产品+器械"协同发展的睡眠健康生态系统，共同探索睡眠障碍预防、治 疗及健康管理的创新模式。通过联合品牌推广及市场拓展，实现互利共赢。 1 根据《深圳证券交易所创业板股票上市规则》及《北京怡和嘉业医疗科技股 份有限公司章程》的相关规定，本协议项下的交易属于公司的日常经营行为，不 构成《上市公司重大资产重组管理办法》规定的重大资产重组，签订本协议无需 提交公司董事会和股东大会审议。 二、合作方基本情况 本公司及董事会全体成员保证信 ...

怡和嘉业（301367）公告，公司与深圳翰宇药业（300199）股份有限公司、深圳翰宇健康科技有限公司 于2025年5月12日共同签署了《战略合作框架协议》。该协议旨在整合优势资源，构建"产品+器械"协同 发展的睡眠健康生态系统，共同探索睡眠障碍预防、治疗及健康管理的创新模式。协议自签字盖章之日 起生效，有效期五年。 ...

Group 1 - Public fund institutions remained active in research activities, with 146 institutions participating in A-share company research from May 5 to May 11, covering 156 stocks across 24 industries, totaling 1198 research instances [1][2] - The mechanical equipment sector stood out, with LeiSai Intelligent (002979) leading with 54 research instances, attracting nearly 30% of public institutions, while Honghua Digital Technology also received 33 instances [1][2] - The pharmaceutical and biological industry was another focus, with three stocks in the top ten, including Baiji Shenzhou, YiHe JiaYe (301367), and AoHua Endoscopy, receiving 49, 44, and 35 research instances respectively, indicating strong market interest in innovative drugs and medical devices [1][2] Group 2 - The electronic, pharmaceutical, and mechanical equipment sectors were the main areas of focus for public fund research, with electronic industry leading at 201 instances, followed by pharmaceutical at 194, and mechanical equipment at 143 [2] - A significant concentration of research activity was noted, with over 60% of public institutions conducting more than four research activities, and nine leading institutions exceeding 20 research instances [2][3] - Among the top ten active public institutions, Penghua Fund Management conducted 28 research instances, focusing on stocks like Naer Shares (002825), Oulutong (300870), and Honghua Digital Technology, which had notable weekly gains [3]

Core Viewpoint - Public fund institutions remain highly active in conducting research on A-share companies, with a total of 146 institutions participating in 1,198 research instances during the week of May 5 to May 11, 2025, covering 156 stocks across 24 primary industries [1]. Group 1: Top Stocks in Research - The top ten stocks with the highest research frequency include: - LeiHan Intelligent (54 times, +3.41%) - BeiGene (49 times, -6.76%) - YiHe JiaYe (44 times, +10.70%) - DeMingLi (37 times, -3.14%) - XiangXin Technology (36 times, +5.32%) - AoHua Endoscopy (35 times, +4.30%) - WenJian Medical (35 times, -1.47%) - HongHua Digital Science (33 times, +8.77%) - XingYe YinXi (31 times, -1.73%) - ZhouDaSheng (29 times, +0.77%) [2]. Group 2: Industry Focus - The mechanical equipment industry stands out with LeiHan Intelligent leading in research frequency, attracting nearly 30% of public institutions [2]. - The pharmaceutical and biotechnology sector is also a major focus, with BeiGene and YiHe JiaYe ranking second and third in research frequency, respectively [3]. - The electronic, pharmaceutical, and mechanical equipment sectors are the primary areas of interest for public fund research, with a total of 538 research instances, accounting for 44.91% of all public fund research activities [3].

Investment Rating - The investment rating for the company is "Buy" and is maintained [1] Core Insights - The company has shown significant improvement in overseas market orders and the name change to "瑞迈特" (Ruimaite) is expected to enhance brand recognition [4][6] - In 2024, the company reported a revenue of 843 million yuan, a decrease of 24.85% year-on-year, and a net profit attributable to the parent company of 155 million yuan, down 47.74% year-on-year. However, in Q1 2025, revenue increased by 38.11% year-on-year to 265 million yuan, and net profit rose by 44.11% to 72 million yuan [4][5] - The company is focusing on integrating brain-machine interface technology with existing products, which could enhance functionality and market competitiveness [6] Company Overview - The latest closing price is 79.90 yuan, with a total market capitalization of 7.2 billion yuan and a circulating market capitalization of 4.5 billion yuan. The company has a debt-to-asset ratio of 17.1% and a price-to-earnings ratio of 45.92 [3] Financial Performance - The company expects revenue growth from 2025 to 2027, with projected revenues of 1.08 billion yuan, 1.29 billion yuan, and 1.54 billion yuan, representing year-on-year growth rates of 28.3%, 19.5%, and 19.4% respectively. Net profit is expected to reach 279 million yuan, 342 million yuan, and 424 million yuan during the same period, with growth rates of 79.4%, 22.7%, and 24.0% respectively [8][10]

Company Overview - Beijing Yihe Jiaye Medical Technology Co., Ltd. was established in 2001 and successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [1] - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [1] - It is a leading domestic enterprise in non-invasive ventilators and masks, with products sold in over 100 countries and regions [1] Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [2] - The company has 202 valid overseas patents, including 39 in the USA and 30 in Europe [2] Financial Performance - In Q1 2025, the company reported a revenue of 265 million CNY, with a quarter-on-quarter growth of 9.90% and a year-on-year growth of 38.11% [3] - Net profit for Q1 2025 was 72 million CNY, showing a quarter-on-quarter increase of 137.70% and a year-on-year increase of 44.11% [3] - The overall gross margin for Q1 2025 was 49.57%, with domestic gross margin at 51.51% and overseas gross margin at 48.47% [3] Market Insights - The company’s consumables business grew by 46.22% year-on-year in 2024, primarily driven by contributions from the USA and Europe [3] - Domestic business revenue and gross margin improved in Q1 2025, indicating a stable and positive trend in the domestic market [4] Product Development - The company has completed the construction of its cloud platform in the European market, connecting with over 20 agents, which lays a foundation for future growth in the mainstream medical insurance market [5] - The newly launched P5 series ventilator has generated sales revenue in Q1 2025 and is expected to positively impact future revenue and gross margin [6] Supply Chain and Innovation - The company has achieved significant localization in core components, enhancing supply chain security and cost advantages [7] - The company is exploring collaborations with Zhejiang Qiang Brain Technology Co., Ltd. to integrate non-invasive brain-machine interface technology with its products [7] Brand Strategy - The company is rebranding from "Yihe Jiaye" to "Ruimaite" to enhance brand recognition and market penetration [8] - The rebranding aims to align the company name with its product brand, reducing confusion among consumers and investors [8]

Investment Rating - The investment rating for the company is "Buy" and it is maintained [1] Core Insights - The company has shown significant improvement in overseas market orders and the name change to "瑞迈特" (Ruimaite) is expected to enhance brand recognition [4][6] - In 2024, the company reported a revenue of 843 million yuan, a year-on-year decrease of 24.85%, and a net profit attributable to the parent company of 155 million yuan, down 47.74% [4] - For Q1 2025, the company achieved a revenue of 265 million yuan, a year-on-year increase of 38.11%, and a net profit of 72 million yuan, up 44.11% [4] - The company is focusing on the integration of brain-machine interface technology with existing products, which is expected to enhance functionality [6] Financial Performance - The company’s domestic revenue in Q1 2025 was 96 million yuan, with a quarter-on-quarter increase of 48.79% and a year-on-year increase of 43.03% [5] - The gross margin for domestic operations in Q1 2025 was 51.51%, up 7.10% year-on-year [5] - The company expects revenue growth from 2025 to 2027 to be 1.082 billion yuan, 1.293 billion yuan, and 1.544 billion yuan, with year-on-year growth rates of 28.3%, 19.5%, and 19.4% respectively [8][10] - The projected net profit for the same period is expected to be 279 million yuan, 342 million yuan, and 424 million yuan, with year-on-year growth rates of 79.4%, 22.7%, and 24.0% respectively [8][10] Valuation Metrics - The company’s price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 25.7, 20.9, and 16.9 respectively [8][10] - The price-to-book (P/B) ratios for the same years are expected to be 2.35, 2.16, and 1.97 [10]

一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 限于防止关联方占用公司资源的制度、募集资金管 | 是 | | 理制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 次（每月一次） 12 | | （2）公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | | | 4.公司治理督导情况 | | | （1）列席公司股东大会次数 | 未列席，已事前或事后审阅相关会议文件 | | （2）列席公司董事会次数 | 未列席，已事前或事后审阅相关会议文件 | | （3）列席公司监事会次数 | 未列席，已事前或事后审阅相关会议文件 | | 5.现场检查情况 | | | （1）现场检查次数 | 次 1 | | （2 ...